a new oral naproxen retard preparation ( 750 mg once daily ) was compared with a standard commercial formula ( 375 mg bid ) in a population of 60 patients affected by osteoarthritis or rheumatoid arthritis .
C0027396
naproxen
C0003873
rheumatoid arthritis